Código QR (código de barras bidimensional)

C059 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Background: The phase 3, randomized trial BRUIN CLL-321 assessed the safety and efficacy of pirtobrutinib vs investigators choice (IC) of idelalisib+rituximab (IdelaR) or bendamustine+rituximab (BR) in patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) pre-treated...

ver descrição completa

Na minha lista:
Principais autores: P. Ghia, D. Rossi, E. Ferrant, F. De La Cruz Vicente, D. Maruyama, V. Banerji, P. Cobb, S. Namburi, R. Greil, A. Loubert, K. Creel, L.M. Hess, N. Payakachat, A.S. Ruppert, D. Wang, P. Abada, C.C. Leow, M. Hill, C.C. Coombs, P. Barr, J.P. Sharman
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2025-09-01
coleção:Haematologica
Acesso em linha:https://haematologica.org/article/view/12823
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados